Searching over 5,500,000 cases.

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Susan A. Poznanovich v. Astrazeneca Pharmaceutials Lp

December 12, 2011


The opinion of the court was delivered by: Pisano, District Judge.


I. Introduction

This is a products liability action brought by Plaintiff Susan Poznanovic against defendants AstraZeneca Pharmaceuticals LP ("AZPLP"), AstraZeneca LP, Astra USA, Inc., KBI Sub Inc., Zeneca, Inc., Astra USA Holdings Corporation, AstraZeneca AB, AstraZeneca PLC, and AstraZeneca UK Limited (collectively, "Defendants"). Plaintiff alleges that she has suffered injuries related to her long term use of Defendants' drug products sold under the brand names Prilosec and Nexium. This matter was originally filed in the Superior Court of New Jersey and then removed to this court by AZPLP. Presently before the Court is Plaintiff's motion to remand. For the reasons below, Plaintiff's motion is denied.

II. Background

This case was commenced in the Superior Court of New Jersey, Law Division, Bergen County, and was subsequently transferred to Superior Court of New Jersey, Law Division, Hunterdon County. On July 12, 2011, before any of the Defendants were served with the summons and complaint, AZPLP removed the action to this Court, alleging diversity jurisdiction under 28 U.S.C. § 1332. There appears to be no dispute that there is complete diversity between Plaintiff, a citizen of Illinois, and Defendants, who comprise citizens of Sweden, United Kingdom, Delaware, New York and New Jersey. On August 3, 2011, Plaintiff timely filed this motion to remand, arguing that removal was improper because the removing defendant, in addition to other defendants, is a citizen of the forum.

III. Analysis

In support of her motion to remand, Plaintiff's principal argument is that the "forum defendant rule," set forth in 28 U.S.C. 1441(b), precludes removal of this case. Under 28 U.S.C. § 1441(a), a defendant may remove a case to a federal court with original jurisdiction over the matter. However, in diversity cases, §1441(b) "imposes another condition above the requirements of original diversity jurisdiction, known as the 'forum defendant rule.' " Sullivan v. Novartis Pharm. Corp., 575 F.Supp.2d 640, 642 (D.N.J. 2008). Under the forum defendant rule, a state court action is not removable based upon diversity jurisdiction if any of the "properly joined and served" defendants are citizens of the forum state. 28 U.S.C. § 1441(b). The relevant statute provides as follows:

Any civil action of which the district courts have original jurisdiction founded on a claim or right arising under the Constitution, treaties or laws of the United States shall be removable without regard to the citizenship or residence of the parties. Any other such action shall be removable only if none of the parties in interest properly joined and served as defendants is a citizen of the State in which such action is brought.

28 U.S.C. 1441(b) (emphasis added). According to Plaintiff, AZPLP is a forum defendant, i.e., a citizen of the state of New Jersey "by virtue of its partnership relationships with AstraZeneca LP and KBI Sub, Inc.," Pl. Brf. at 2, and therefore cannot properly remove a case to this Court where jurisdiction is founded on diversity of citizenship. AZPLP, on the other hand, contends that it is not a forum defendant but, in any event, removal was proper under the plain language of the statute because no forum defendant in the matter had been "properly joined and served" at the time of removal. Indeed, there is no dispute that at the time this matter was removed Plaintiff had not served the complaint on any defendant. Nevertheless, Plaintiff responds that AZPLP should not be permitted defeat the forum defendant rule through what Plaintiff describes as "gamesmanship," that is, monitoring court filings and removing an action before a plaintiff has the opportunity to effect service. Plaintiff contends that sanctioning removal in this case would be contrary to the intent of the "properly joined and served" language of § 1441(b), which according to Plaintiff is intended to prevent fraudulent joinder of a forum defendant by a plaintiff for the sole purpose of blocking removal.

Putting aside for the moment the issue of whether AZPLP is a forum defendant, the Court notes that both parties' positions on the propriety of AZPLP's removal find support in case law. Indeed, in applying § 1441(b), courts in this district and elsewhere are split as to whether a forum defendant may remove a case to federal court prior to being formally served with the complaint. Compare, e.g., Ripley v. Eon Labs, Inc., 622 F. Supp. 2d 137 (D.N.J. 2007) (finding removal by forum defendant prior to service proper under plain language of statute because forum defendants had not been "properly joined and served"), with Sullivan v. Novartis Pharms. Corp., 575 F. Supp. 2d 640 (D.N.J. 2008) (remanding case removed by forum defendant, finding that the literal application of § 1441(b) would produce results Congress could not have intended). To the extent that some courts that have noted the distinction, courts are also split on the question of whether a non-forum defendant may remove a case where a plaintiff has joined, but has not served, a forum defendant. See North v. Precision Airmotive Corp., 600 F. Supp. 2d 1263, 1268 (M.D. Fla. 2009) (collecting cases). In any event, to the extent that the distinction may be relevant, the first question for the Court to resolve is whether AZPLP is a forum defendant.

AZPLP is a limited partnership. Unlike a corporation, which is deemed to be a citizen of both the state in which it is incorporated and the place where it has its principal place of business, partnerships and other unincorporated entities are not considered "citizens" for purpose of diversity jurisdiction. Swiger v. Allegheny Energy, Inc., 540 F.3d 179, 184 (3rd Cir. 2008). Rather, the longstanding rule with regard to partnerships and unincorporated associations is that a court is to look to the citizenship of all of the partners or members comprising the entity. Id.; see also Zambelli Fireworks Mfg. Co., Inc. v. Wood, 592 F.3d 412 (3d Cir. 2010) ("[A] partnership, as an unincorporated entity, takes on the citizenship of each of its partners.") Applying that rule here, it is clear that AZPLP is not a forum defendant, as none of its partners, all of whom are corporations, are citizens of New Jersey. AZPLP is comprised of four partners. AstraZeneca AB, the general partner, is a corporation organized in and having its principal place of business in Sweden. AZPLP's three limited partners are (1) Zeneca Inc., which is organized in and has its principal place of business in Delaware; (2) Astra U.S. Holding Corporation, which is organized in and has its principal place of business in Delaware; and (3) Astra USA Inc., which is organized in New York and has its principal place of business in Delaware.

Plaintiff, in asserting that AZPLP is a forum defendant, appears to misconstrue the relevant rule. Plaintiff does not dispute that the partners comprising AZPLP are not citizens of New Jersey. Nevertheless, Plaintiff contends that AZPLP is somehow a forum defendant because of AZPLP's relationship AstraZeneca LP and KBI Sub, Inc., both of whom are forum defendants. AZPLP is the general partner of AstraZeneca LP, while KBI Sub, Inc., is a limited partner. AstraZeneca LP is comprised only of these two entities. KBI Sub, Inc. has its principal place of business in New Jersey, thus is a citizen of the forum (and, therefore, a forum defendant). As such, AstraZeneca LP is also considered a citizen of the forum. While it is unclear to the Court whether Plaintiff is arguing that AZPLP must be deemed to be a forum defendant because it is the general partner of a forum defendant or because AZPLP is in a partnership with a forum defendant, in either case Plaintiff is wrong. AZPLP's relationship with these entities are not relevant for the "citizenship" purposes here. Rather, the Court must look to the partners comprising AZPLP, and, in doing so, finds AZPLP is not a forum defendant.

The Court turns now to the precise question raised by Plaintiff's motion, i.e., whether removal by a non-forum defendant prior to formal service on any defendant, including forum defendants, is valid. Courts within this district and elsewhere are sharply split on the issue of pre-service removal (whether by a forum or non-forum defendant), and the decisions generally fall into two camps. The first group, and those that comprise a majority in this district, are those decisions that have allowed removal prior to service upon a forum defendant based upon the plain language of the statute. See, e.g., Bivins v. Novartis Pharmaceuticals Corp., 2009 WL 2496518 (D.N.J. Aug. 10, 2009) (Kugler, J.) ("Here the statutory language is clear: removal is prohibited only where a defendant, who is a resident of the forum state, has been properly joined and served.") (internal quotations omitted, emphasis in original); Ripley v. Eon Labs, Inc., 622 F. Supp.2d 137, 141-42 (D.N.J. 2007) (Rodriguez, J.) (The plain language of . § 1441(b), despite the numerous policy arguments against it, permits removal of this case . to this Court."); Yocham v. Novartis Pharmaceuticals Corp., 2007 WL 2318493 at *3 (D.N.J. Aug. 13, 2007) (Simandle, J.) (denying remand motion based upon "a plain reading of § 1441(b) and straightforward application of it"); Jaegar v. Schering Corp., 2007 WL 3170125 at *2 (D.N.J. Oct. 25, 2007) (Cavanaugh, J.) ("[T]here is no dispute that Defendants were not served at the time removal was file. Accordingly, there is no applicable limitation on Defendants' right to remove the matter to this Court."); Thomson v. Novartis Pharmaceuticals Corp., 2007 WL 1521138 (D.N.J. May 22, 2007) (Simandle, J.) (denying remand based upon a "plain reading of § 1441(b) and a straightforward application of it"); Frick v. Novartis Pharmaceuticals Corp., 2006 WL 454360, at *3 (D.N.J. Feb. 23, 2006) (Debevoise, J.) ("[W]e find that the language of the statute is unambiguous [and] it is not readily apparent that applying the clear language of the statute to the present case would produce a result that is demonstrably at odds with the intentions of Congress."). While many of these decisions acknowledge in some way the "colorable policy arguments that it is unjust that a properly joined defendant could monitor state court dockets and remove cases prior to being served, and that it makes little sense to provide a federal forum to an in-state defendant upon removal of a diversity case," Thompson, 2007 WL 1521138 at *4, these decisions found such arguments to be insufficient to overcome the requirement that a court give meaning to the plain language of a statute. As explained by the Bivins court, The role of the courts in interpreting a statute is to give effect to Congress's intent. Because it is presumed that Congress expresses its intent through the ordinary meaning of its language, every exercise of statutory interpretation begins with plain language of the statute itself. Where the statutory language is plain and unambiguous, further inquiry is not required, except in the extraordinary case where a literal reading of the language produces an absurd result. Moreover, a court may depart from the plain language of a statute only by an extraordinary showing of a contrary congressional intent in the legislative history.

Bivins, 2009 WL 2496158 *2 (quoting Idahoan Fresh v. Advantage Produce, Inc., 157 F.3d 197, 202 (3d Cir. 1998)). The decisions falling into this first group generally have rejected the argument like that made by Plaintiff here that a literal application of the statute would lead ...

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.